Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.82 Million CHF | -92.5% |
| 2022 | 131 Million CHF | -16.11% |
| 2021 | 156.17 Million CHF | -6.42% |
| 2020 | 166.89 Million CHF | -13.11% |
| 2019 | 192.07 Million CHF | -9.83% |
| 2018 | 213.01 Million CHF | -11.18% |
| 2017 | 239.82 Million CHF | 20.98% |
| 2016 | 198.23 Million CHF | -14.64% |
| 2015 | 232.23 Million CHF | 9.23% |
| 2014 | 212.61 Million CHF | 101.96% |
| 2013 | 105.27 Million CHF | 16.49% |
| 2012 | 90.37 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 9.82 Million CHF | -92.5% |
| 2023 Q3 | 9.82 Million CHF | -81.5% |
| 2023 Q2 | 53.13 Million CHF | 0.0% |
| 2023 Q1 | 53.13 Million CHF | -59.44% |
| 2023 Q4 | 9.82 Million CHF | 0.0% |
| 2022 Q1 | 140.18 Million CHF | -10.24% |
| 2022 FY | 131 Million CHF | -16.11% |
| 2022 Q3 | 131 Million CHF | -6.55% |
| 2022 Q4 | 131 Million CHF | 0.0% |
| 2022 Q2 | 140.18 Million CHF | 0.0% |
| 2021 Q3 | 156.17 Million CHF | 0.03% |
| 2021 Q4 | 156.17 Million CHF | 0.0% |
| 2021 FY | 156.17 Million CHF | -6.42% |
| 2021 Q1 | 156.12 Million CHF | -6.45% |
| 2021 Q2 | 156.12 Million CHF | 0.0% |
| 2020 Q3 | 166.89 Million CHF | -5.89% |
| 2020 Q4 | 166.89 Million CHF | 0.0% |
| 2020 FY | 166.89 Million CHF | -13.11% |
| 2020 Q1 | 177.33 Million CHF | -7.67% |
| 2020 Q2 | 177.33 Million CHF | 0.0% |
| 2019 Q1 | 200.98 Million CHF | -5.65% |
| 2019 Q4 | 192.07 Million CHF | 0.0% |
| 2019 Q2 | 200.98 Million CHF | -0.0% |
| 2019 FY | 192.07 Million CHF | -9.83% |
| 2019 Q3 | 192.07 Million CHF | -4.43% |
| 2018 Q4 | 213.01 Million CHF | 0.0% |
| 2018 Q2 | 234.56 Million CHF | 0.0% |
| 2018 Q1 | 234.56 Million CHF | -2.19% |
| 2018 FY | 213.01 Million CHF | -11.18% |
| 2018 Q3 | 213.01 Million CHF | -9.19% |
| 2017 Q2 | 174.29 Million CHF | 0.0% |
| 2017 FY | 239.82 Million CHF | 20.98% |
| 2017 Q3 | 239.82 Million CHF | 37.6% |
| 2017 Q4 | 239.82 Million CHF | 0.0% |
| 2017 Q1 | 174.29 Million CHF | -12.08% |
| 2016 Q4 | 198.23 Million CHF | 0.0% |
| 2016 FY | 198.23 Million CHF | -14.64% |
| 2016 Q3 | 198.23 Million CHF | -6.78% |
| 2016 Q2 | 212.66 Million CHF | 0.0% |
| 2016 Q1 | 212.66 Million CHF | -8.43% |
| 2015 FY | 232.23 Million CHF | 9.23% |
| 2015 Q1 | 190.99 Million CHF | -10.17% |
| 2015 Q2 | 190.99 Million CHF | 0.0% |
| 2015 Q4 | 232.23 Million CHF | 0.0% |
| 2015 Q3 | 232.23 Million CHF | 21.59% |
| 2014 Q4 | 212.61 Million CHF | 0.0% |
| 2014 Q1 | 136.77 Million CHF | 29.93% |
| 2014 Q2 | 136.77 Million CHF | 0.0% |
| 2014 Q3 | 212.61 Million CHF | 55.44% |
| 2014 FY | 212.61 Million CHF | 101.96% |
| 2013 Q4 | 105.27 Million CHF | 0.0% |
| 2013 Q1 | 114.67 Million CHF | 26.89% |
| 2013 FY | 105.27 Million CHF | 16.49% |
| 2013 Q2 | 114.67 Million CHF | 0.0% |
| 2013 Q3 | 105.27 Million CHF | -8.2% |
| 2012 FY | 90.37 Million CHF | 0.0% |
| 2012 Q4 | 90.37 Million CHF | 0.0% |
| 2012 Q3 | 90.37 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 74.7% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -36.129% |
| SQZ Biotechnologies Company | 107.18 Million USD | 90.831% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 6.877% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 92.452% |
| Mesoblast Limited | 667.9 Million USD | 98.528% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -13481.427% |
| Genus plc | 1.02 Billion USD | 99.045% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -623.538% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1869.425% |
| Marizyme, Inc. | 22.01 Million USD | 55.357% |
| ContraFect Corporation | 20.67 Million USD | 52.473% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1467.496% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2417.689% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2471.636% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -586.311% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -137.051% |
| MultiCell Technologies, Inc. | 126.22 USD | -7786463.144% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -945.899% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 92.352% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2176.553% |
| Q BioMed Inc. | 3.51 Million USD | -179.566% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 72.062% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1175.323% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3661.602% |
| Biomind Labs Inc. | 73.81 Thousand USD | -13213.916% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 97.877% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 67.256% |
| Skye Bioscience, Inc. | 11.94 Million USD | 17.69% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -196.655% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -257.866% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -401.903% |
| IMV Inc. | 31.33 Million USD | 68.634% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1329.585% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -277.544% |
| GB Sciences, Inc. | 103.44 Thousand USD | -9401.17% |
| Alpha Cognition Inc. | 2.45 Million USD | -300.796% |
| HST Global, Inc. | 1526.00 USD | -643949.803% |
| CSL Limited | 38.02 Billion USD | 99.974% |
| Halberd Corporation | 10.13 Thousand USD | -96911.154% |
| Enzolytics Inc. | 361.7 Million USD | 97.283% |
| Resverlogix Corp. | 8.11 Million USD | -21.112% |
| Affymax, Inc. | 7.44 Million USD | -32.046% |
| SYBLEU INC | 330.46 Thousand USD | -2874.025% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -423.367% |
| argenx SE | 4.54 Billion USD | 99.784% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 64.829% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 79.397% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -43042.092% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -9.823% |
| AVAX Technologies, Inc. | 7.37 Million USD | -33.225% |
| Zenith Capital Corp. | 7410.00 USD | -132534.278% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.71% |
| Ember Therapeutics, Inc. | 184.00 USD | -5341313.043% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2954.076% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3660.35% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.798% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -578.348% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -224.89% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 81.351% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -959.118% |
| BioStem Technologies, Inc. | 14.56 Million USD | 32.5% |
| ONE Bio Corp. | 70.08 Million USD | 85.977% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -17114.068% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -425363.203% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -894.79% |
| Agentix Corp. | 261.39 Thousand USD | -3659.947% |
| LadRx Corporation | 2.3 Million USD | -325.854% |
| Cell Source, Inc. | 195.17 Thousand USD | -4935.687% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1945.168% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2679.335% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2679.335% |
| NovAccess Global Inc. | 62.24 Thousand USD | -15688.78% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1436.482% |
| Itoco Inc. | 1.4 Million USD | -601.978% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -10174.418% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -9171.887% |
| Kadimastem Ltd | 2.3 Million USD | -326.556% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -12771.886% |
| CytoDyn Inc. | 11.13 Million USD | 11.744% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -6774.213% |
| Mobile Lads Corp. | 52.00 USD | -18900284.615% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -54867.562% |
| Qrons Inc. | 420.00 USD | -2339947.619% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2449.66% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1680.084% |
| Rebus Holdings, Inc. | 5000.00 USD | -196464.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2300.506% |
| International Stem Cell Corporation | 5.39 Million USD | -82.341% |
| Bioxytran, Inc. | 137.63 Thousand USD | -7040.615% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 34.487% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 40.719% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -12340.759% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1036.633% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -30.746% |
| Neutra Corp. | 2851.00 USD | -344628.166% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 69.672% |
| PureTech Health plc | 693.97 Million USD | 98.584% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -21.77% |
| IXICO plc | 15.84 Million USD | 37.969% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -18.669% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.488% |
| CSL Limited | 38.02 Billion USD | 99.974% |
| Cellectis S.A. | 333.99 Million USD | 97.057% |